1 edition of Urokinase pulmonary embolism trial found in the catalog.
Urokinase pulmonary embolism trial
|Statement||Editorial committee: Arthur A. Sasahara, chairman [and others]|
|Series||American Heart Association. Monograph, no. 39, Supplement 2 to Circulation, v. 47-48, April,, 1973, Circulation., 1973, no. 2., American Heart Association monograph ;, no. 39.|
|Contributions||Sasahara, Arthur A. 1927- ed.|
|LC Classifications||RC776.P85 U76|
|The Physical Object|
|Number of Pages||108|
|LC Control Number||73075149|
Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol. Jan (2. New York, McGraw-Hill Book Co Inc, , pp 8. American Heart Association National Cooperative Study: The urokinase pulmonary embolism trial: Chapter X. Clinical and electrocardiographic observations. Circulation 47((suppl 2)), 9. Israel HL, Goldstein F: The varied clinical manifestations of pulmonary embolism.
The first large prospective randomized trial was the Urokinase Pulmonary Embolism Trial (UPET).4 A total of patients with angiographically documented PE were divided into . sponsored Urokinase Pulmonary Embolism Trial (UPET) were published In this large, prospective, level I trial, patients with angiographically doc-umented PE were randomized to receive either a h infusion of UK followed by heparin or heparin alone. At 24 h, the degree of improvement in hemodynamic measurements and pulmonary blood.
Warning. If possible before you receive urokinase, tell your doctor if you have a brain tumor or aneurysm, hemophilia or other bleeding disorder, high blood pressure, or if you have recently had a stroke, brain or spinal surgery, or medical emergency requiring CPR (cardiopulmonary resuscitation).. In an emergency situation it may not be possible to tell your caregivers about your . In considering a possible diagnosis of acute pulmonary embolism (PE), it is helpful to consider the patient in terms of the mode of presentation. 1 x 1 Stein, PD, Willis, PW III, and DeMets, DL. History and physical examination in acute pulmonary embolism in patients without preexisting cardiac or pulmonary disease.
Chaucer the maker
teacher as a professional in a developing country
It all began with God
Test Set 2 Psy&life Br 9th-P
Chips for everything:bBritains opportunities in a key global market
The Best of Photojournalism
Pastoral letter addressed by D.J. Cardinal Mercier archbishop of Malines to the clergy and laity of the Archdiocese of Malines
Original Article from The New England Journal of Medicine — Urokinase in Pulmonary Embolism. Fletcher and his associates 2 showed in a small clinical trial that this form of therapy was safe Cited by: Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.
Marini C(1), Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Author information: (1)Pulmonary Unit, University of Pisa, Italy.
Dissolution of pulmonary emboli with heparin and urokinase is ascribed, respectively, to anticoagulation and Cited by: In a randomized, national cooperative trial, urokinase and subsequent heparin sodium therapy, when Urokinase pulmonary embolism trial book to heparin therapy alone, significantly accelerated the resolution rate of pulmonary thromboemboli at 24 hours as shown by pulmonary arteriograms, lung scans, and right-sided pressure measurements.
No significant differences in recurrence rate of pulmonary embolism. To the Editor.— A hour infusion of urokinase was shown to accelerate the resolution rate of pulmonary thromboemboli more than did a similar infusion of heparin (, ).
However, " urokinase regimen did not usually achieve complete thrombolysis." The lack of dramatic thrombolysis may well be ascribed to the short duration of the urokinase by: A preliminary report regarding the results of the Urokinase-Pulmonary Embolism Trial appeared in JAMA 1 in The entire concept, specific aims, and results of this trial were published in Circulation 2 in Still, there remains a misconception regarding the purpose of this Urokinase pulmonary embolism trial book and there have been gross misinterpretations of the results.
3 This study was not a therapeutic trial, and Cited by: 3. the Urokinase Pulmonary Embolism Trial (2) and approved by the U.S. Food and Drug Administration in (that is, 4, U/kg as an intravenous bolus infusion, followed by. The urokinase pulmonary embolism trial: A national cooperative study.
Circulation. ; II–II [Google Scholar] Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
The dose of urokinase ('Abbokinase' Abbott) was that specified for phase I of the Urokinase Pulmonary Embolism Trial (UPET): U/lb body-weight as an intravenous bolus dose followed by U/Ib/h for 24 h.6 Our protocol required discontinuation of urokinase after 2 h of therapy if the 2 h angiogram was judged to show any clot lysis; if there was no evidence of clot lysis then.
Background: Systemic thrombolysis for acute pulmonary embolism (PE) carries up to a 20% risk of major bleeding, including a 2% to 5% risk of hemorrhagic stroke.
We evaluated the safety and effectiveness of catheter-directed therapy (CDT) as an alternative treatment of acute PE. Methods: One hundred one consecutive patients receiving CDT for acute PE were prospectively enrolled in a.
Inthe Urokinase Pulmonary Embolism Trial (UPET) was conducted to define the efficacy of thrombolytic therapy in PE. 63 In this randomized prospective controlled trial, patients were randomized to standard IV heparin therapy with and without an infusion of urokinase.
Using pulmonary angiograms, lung scans, and right-sided pressure measurements, no significant differences in the. Meyer G, Sors H, Charbonnier B, et al.
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. ; – Pulmonary embolism occurs when a detached thrombus (embolism) from any part of the venous territory becomes lodged in the pulmonary artery.
Although the origin of the embolism may be venous thrombosis in any location (upper extremities, prostatic, uterine and renal veins and right heart chambers), it is a lower extremity deep vein thrombosis in. The Urokinase pulmonary embolism trial; a national cooperative study.
[Arthur A Sasahara;] Home. WorldCat Home About WorldCat Help. Search. Search for Library Items Search for Lists Search for Contacts Search for a Library.
Create Book\/a>, schema:CreativeWork\/a>. Pulmonary embolism (PE) remains poorly understood. Rates of clinical outcomes such as death and recurrence vary widely among trials. We therefore established the International Cooperative Pulmonary Embolism Registry (ICOPER), with.
Soloff LA, Rodman T. Acute pulmonary embolism. Clinical. Am Heart J. Dec; 74 (6)– Tow DE, Wagner HN., Jr Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med. May 11; (19)– Walsh PN, Stengle JM, Sherry S.
The urokinase-pulmonary embolism trial. Circulation. The history and physical examination were assessed in patients with acute pulmonary embolism uncomplicated by preexisting cardiac or pulmonary disease. The patients had been included in the Urokinase Pulmonary Embolism Trial or the Urokinase-Streptokinase Embolism Trial.
Abstract. In the s, both the Urokinase Pulmonary Embolism and Urokinase-Streptokinase Pulmonary Embolism trials began the quest to develop thrombolytic therapy for the treatment of acute massive and submassive pulmonary embolism (PE).
The goals of these studies were the immediate reduction in clot burden, restoration of hemodynamic stability, and improved survival. Simon, Plain film and angiographic aspects of pulmonary embolism K.M. Moser, M. Stein, Pulmonary Thromboembolism () Year Book Medical Publishers Chicago G.T.
Smith, L. Dexter, G.J. Dammin, Postmortem quantitative studies in pulmonary embolism A.A. Sasahara, M. Stein, Pulmonary Embolic Disease () Grune & Stratton New York The combination of pulmonary embolism unlikely and a normal D-dimer test result occurred in patients (%), of whom were not treated with anticoagulants; subsequent nonfatal VTE.
The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 47Suppl 2:ll-1, 2. The Urokinase-Streptokinase Pulmonary Embolism Trial: phase 2 results. A cooperative study. JAMA3.
Salzman EW, Deykin D, Shapiro RM, Rosenberg R Manage- ment of heparin therapy. N Engl J Med4. Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial.
Respir Res. Dec 29; doi: / Layout table for additonal information. Acute massive pulmonary embolism. An initial loading dose of 4, IU/kg body weight dissolved in 15 ml solvent should be infused in a peripheral vein over 10 minutes followed by 4, IU/kg/hour for 12 hours.
Alternatively, a bolus injection into the pulmonary artery repeated for up to 2 times at hour intervals may be used. It is unclear whether r-SK can be used in patients with pulmonary embolism (PE).
The aim of this study was to investigate the efficacy and safety of million IU r-SK by 2 hours infusion IU/kg urokinase (UK) by 2 hours infusion in selected PE patients.